ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.

Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomovitz B, ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators

Open source

DOI: 10.1016/j.annonc.2024.08.2242
Published: 2024 Nov
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2024.08.2242,
  title = {ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.},
  author = {Van Gorp T and Cibula D and Lv W and Backes F and Ortaç F and Hasegawa K and Lindemann K and Savarese A and Laenen A and Kim YM and Bodnar L and Barretina-Ginesta MP and Gilbert L and Pothuri B and Chen X and Flores MB and Levy T and Colombo N and Papadimitriou C and Buchanan T and Hanker LC and Eminowicz G and Rob L and Black D and Lichfield J and Lin G and Orlowski R and Keefe S and Lortholary A and Slomovitz B and ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators},
  year = {2024},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2024.08.2242},
  url = {https://doi.org/10.1016/j.annonc.2024.08.2242}
}

RIS

TY  - JOUR
TI  - ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.
AU  - Van Gorp T
AU  - Cibula D
AU  - Lv W
AU  - Backes F
AU  - Ortaç F
AU  - Hasegawa K
AU  - Lindemann K
AU  - Savarese A
AU  - Laenen A
AU  - Kim YM
AU  - Bodnar L
AU  - Barretina-Ginesta MP
AU  - Gilbert L
AU  - Pothuri B
AU  - Chen X
AU  - Flores MB
AU  - Levy T
AU  - Colombo N
AU  - Papadimitriou C
AU  - Buchanan T
AU  - Hanker LC
AU  - Eminowicz G
AU  - Rob L
AU  - Black D
AU  - Lichfield J
AU  - Lin G
AU  - Orlowski R
AU  - Keefe S
AU  - Lortholary A
AU  - Slomovitz B
AU  - ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators
PY  - 2024
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2024.08.2242
UR  - https://doi.org/10.1016/j.annonc.2024.08.2242
ER  -

APA

T, V. G., D, C., W, L., F, B., F, O., K, H., K, L., A, S., A, L., YM, K., L, B., MP, B., L, G., B, P., X, C., MB, F., T, L., N, C., C, P., T, B., LC, H., G, E., L, R., D, B., J, L., G, L., R, O., S, K., A, L., B, S., & investigators, E. (2024). ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2024.08.2242

Source records

pubmed · retrieved 2026-09-26T15:41:25.078Z
europe-pmc · retrieved 2026-09-26T15:41:25.070Z